- Title
- A phase 2 study of single agent ibrutinib for first-line treatment of chronic graft-versus-host disease: A new paradigm and lessons learned
- Creators
- Najla El Jurdi - National Cancer InstituteNoa G. Holtzman - University of MiamiRania Hishmeh - National Institutes of HealthAlain Mina - National Institutes of HealthEduard Schulz - National Cancer InstituteAnita Stokes - National Cancer InstituteGrace Li - National Cancer InstituteKeith T. Schmidt - National Cancer InstituteWilliam D. Figg - National Cancer InstituteNicholas Micheletti - BiostatJacqueline W. Mays - National Institute of Dental and Craniofacial ResearchEdward W. Cowen - National Institute of Arthritis and Musculoskeletal and Skin DiseasesSteven Z. Pavletic - National Cancer InstituteIskra Pusic - Washington University in St. Louis
- Publication Details
- British journal of haematology, Vol.206(6), pp.1822-1827
- Publisher
- Wiley
- Number of pages
- 6
- Grant note
- This work was supported by funding from the Intramural Research Program, National Institutes of Health, Center for Cancer Research, National Cancer Institute, Center for Cancer Research, also through a Collaborative Research Agreement between Pharmacyclics
- Academic Unit
- Miller School of Medicine; UMMG Department of Medicine
- Language
- English
- Resource Type
- Journal article
- PMID
- 40322855
- Record Identifier
- 991032796181102976
Journal article
A phase 2 study of single agent ibrutinib for first-line treatment of chronic graft-versus-host disease: A new paradigm and lessons learned
British journal of haematology, Vol.206(6), pp.1822-1827
2025-06-01
PMID: 40322855
Metrics
1 Record Views